Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPR741 DDI with Antibiotics in Healthy Volunteers
NCT03376529Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SPR741 in gram-negative bacterial infections (3 arms), sponsored by Spero Therapeutics. Primary endpoints: Maximum concentration, Area under the concentration-time curve from time 0 to last measurable time-point and 6 more. Started Nov 2017; status: completed.
02
Drugs
SPR741
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT03376529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03376529.